View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBiocept 配当と自社株買い配当金 基準チェック /06Biocept配当金を支払った記録がありません。主要情報n/a配当利回り-153.1%バイバック利回り総株主利回り-153.1%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Oct 26Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite IndexBiocept, Inc. will be removed from NASDAQ Composite Index.お知らせ • Oct 21Biocept's Securities To Be Delisted from NasdaqOn October 16, 2023, Biocept, Inc. received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined that the Company’s securities will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, in connection with the filing of a voluntary case under Chapter 7 of Title 11 of the United States Bankruptcy Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 2023. Pursuant to the Delisting Notice, Nasdaq’s decision was based on the following factors: (i) The public interest concerns raised by the filing; (ii) concerns regarding the residual equity interest of the existing listed securities holders; and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, on May 17, 2023, Staff also notified the Company that it failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing pursuant to Listing Rule 5550(b)(1), which deficiency serves as an additional and separate basis for delisting. The Staff letter indicates that the trading of the Company’s common stock and warrants will be suspended at the opening of business on October 25, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to appeal the determination and, therefore, it is expected that its Common Stock will be delisted, which would not affect any actions it may take in bankruptcy. Trading of the Common Stock will be suspended by Nasdaq at the opening of business on October 25, 2023.お知らせ • Oct 19Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI IndexBiocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Indexお知らせ • Sep 22Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung CancerBiocept, Inc. announced the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. The FORESEE trial is specifically designed to measure the impact of CNSide on physicians' clinical decisions to generate the data needed to help reach this goal. FORESEE is a two-part prospective clinical trial designed to follow subjects and collect data from each enrollee at four key time points in their treatment, as well as to compare CNSide cell detection in the cerebrospinal fluid to that of conventional cytology. CNSide has notable advantages over current standards of care, such as cytology, clinical evaluation and MRI, which have limited sensitivity and specificity. Biocept expects to have results from the feasibility phase of the FORESEE trial in the first half of 2024 and to then begin enrolling between 40 and 100 subjects in the trial's validation phase. Enrollment is currently open at four clinical sites with two additional sites expected to join the FORESEE trial in The near term.New Risk • Aug 17New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: US$1.4m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$19m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (327% increase in shares outstanding). Market cap is less than US$10m (US$2.24m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.6m net loss in 3 years). Revenue is less than US$5m (US$1.4m revenue).Reported Earnings • Aug 16Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)Second quarter 2023 results: US$3.50 loss per share (improved from US$16.83 loss in 2Q 2022). Net loss: US$3.63m (loss narrowed 62% from 2Q 2022). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.お知らせ • Jun 21+ 1 more updateBiocept, Inc. Announces Executive ChangesBiocept, Inc. has named Antonino Morales as President effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer, and Director. Mr. Morales has served as a member of Biocept's Board since July 2021 and was a member of the Audit Committee from August 2021 until his appointment as interim Chief Financial Officer. He has more than 30 years of broad executive leadership experience and has served in executive management or consulting roles with various Fortune 100 companies, including Citibank, Bank of America, Arthur Andersen, Mazda North America and McDonald's. Mr. Morales has also led multiple private equity-backed startup companies. He received a Bachelor of Science in Finance from the University of Southern California and is a licensed CPA.お知らせ • May 16Biocept Expects to Receive Non-Compliance Notice Form NasdaqAs reported in Biocept, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on May 10, 2023, the Company's stockholders' equity as of March 31, 2023 was $2.4 million. As a result, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirements set in Nasdaq Stock Market Rule 5550(b) (the Rule"). The Company expects to receive a formal notice (the Notice") from The Nasdaq Stock Market LLC (Nasdaq") on or about May 15, 2023 to formally notify the Company of non-compliance with the Rule. The Company discussed the noncompliance with the Rule with Nasdaq on May 12, 2023. Pursuant to the Notice and Nasdaq rules, the Company will have 45 calendar days after receipt of the Notice to submit a plan to regain compliance with the Rule. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to provide evidence of compliance. There can be no assurance that the Company will be able to regain compliance with the Rule.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.Breakeven Date Change • Apr 18No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.分析記事 • Apr 17Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For GrowthThose holding Biocept, Inc. ( NASDAQ:BIOC ) shares would be relieved that the share price has rebounded 48% in the last...Breakeven Date Change • Feb 14Forecast to breakeven in 2025The 2 analysts covering Biocept expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$5.04m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$2.16, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 79% over the past three years.Reported Earnings • Feb 17Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2021 results: US$0.041 loss per share (up from US$0.37 loss in 3Q 2020). Revenue: US$17.5m (up 165% from 3Q 2020). Net loss: US$624.7k (loss narrowed 87% from 3Q 2020). Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 37% compared to a 187% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$3.95, the stock trades at a trailing P/E ratio of 21.5x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 65% over the past three years.分析記事 • Nov 23Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True PositionEven though Biocept, Inc. ( NASDAQ:BIOC ) posted strong earnings recently, the stock hasn't reacted in a large way. We...Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$34.9m (up 431% from 3Q 2020). Net income: US$854.1k (up US$5.73m from 3Q 2020). Profit margin: 2.4% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.分析記事 • Aug 19Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) EarningsCelebrations may be in order for Biocept, Inc. ( NASDAQ:BIOC ) shareholders, with the covering analyst delivering a...Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$12.0m (up US$11.1m from 2Q 2020). Net loss: US$1.83m (loss narrowed 72% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.分析記事 • Jul 03Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time BeingIn the past three years, the share price of Biocept, Inc. ( NASDAQ:BIOC ) has struggled to grow and now shareholders...Major Estimate Revision • May 19Consensus revenue estimates increase to US$37.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$28.4m to US$37.5m. Forecast losses expected to reduce from -US$1.17 to -US$0.82 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$12.00 unchanged from last update. Share price was steady at US$4.59 over the past week.Reported Earnings • May 13First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$17.8m (up US$16.3m from 1Q 2020). Net income: US$2.60m (up US$10.9m from 1Q 2020). Profit margin: 15% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.Price Target Changed • May 09Price target decreased to US$12.00Down from US$20.30, the current price target is provided by 1 analyst. New target price is 161% above last closing price of US$4.61. Stock is up 12% over the past year.Reported Earnings • Mar 31Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$27.5m (up 397% from FY 2019). Net loss: US$17.8m (loss narrowed 30% from FY 2019). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.分析記事 • Mar 13Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price GainBiocept, Inc. ( NASDAQ:BIOC ) shareholders might be concerned after seeing the share price drop 19% in the last month...Is New 90 Day High Low • Feb 05New 90-day high: US$6.70The company is up 51% from its price of US$4.45 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.分析記事 • Jan 26We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, Biocept ( NASDAQ:BIOC ) stock...Is New 90 Day High Low • Jan 20New 90-day high: US$6.23The company is up 38% from its price of US$4.52 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.分析記事 • Dec 22Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?With the business potentially at an important milestone, we thought we'd take a closer look at Biocept, Inc.'s...Reported Earnings • Nov 20Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$6.59m (up 331% from 3Q 2019). Net loss: US$4.88m (loss narrowed 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 71% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Nov 20Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 163%. Earnings per share (EPS) missed analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 154%, compared to a 365% growth forecast for the Biotechs industry in the US.Reported Earnings • Nov 17Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$6.59m (up 331% from 3Q 2019). Net loss: US$4.88m (loss narrowed 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 71% per year, which means it is significantly lagging earnings.Analyst Estimate Surprise Post Earnings • Nov 17Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 163%. Earnings per share (EPS) missed analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 154%, compared to a 365% growth forecast for the Biotechs industry in the US.Major Estimate Revision • Nov 14Analysts update estimatesThe 2020 consensus revenue estimate increased from US$8.33m to US$11.7m. Earning per share (EPS) estimate was further reduced from -US$1.35 to -US$2.11 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target was lowered from US$20.30 to US$20.00. Share price is up 7.4% to US$4.78 over the past week.決済の安定と成長配当データの取得安定した配当: BIOCの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BIOCの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Biocept 配当利回り対市場BIOC 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BIOC)n/a市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Biotechs)2.4%アナリスト予想 (BIOC) (最長3年)n/a注目すべき配当: BIOCは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BIOCは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BIOCの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BIOCが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/10/15 00:54終値2023/10/13 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Biocept, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Raghuram SelvarajuAegis Capital CorporationSally YanchusBrookline Capital MarketsKumaraguru RajaBrookline Capital Markets4 その他のアナリストを表示
お知らせ • Oct 26Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite IndexBiocept, Inc. will be removed from NASDAQ Composite Index.
お知らせ • Oct 21Biocept's Securities To Be Delisted from NasdaqOn October 16, 2023, Biocept, Inc. received a letter (“Delisting Notice”) from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff had determined that the Company’s securities will be delisted from Nasdaq pursuant to Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, in connection with the filing of a voluntary case under Chapter 7 of Title 11 of the United States Bankruptcy Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 2023. Pursuant to the Delisting Notice, Nasdaq’s decision was based on the following factors: (i) The public interest concerns raised by the filing; (ii) concerns regarding the residual equity interest of the existing listed securities holders; and (iii) concerns about the Company’s ability to sustain compliance with all requirements for continued listing on Nasdaq. Specifically, on May 17, 2023, Staff also notified the Company that it failed to maintain a minimum of $2,500,000 in stockholders’ equity required for continued listing pursuant to Listing Rule 5550(b)(1), which deficiency serves as an additional and separate basis for delisting. The Staff letter indicates that the trading of the Company’s common stock and warrants will be suspended at the opening of business on October 25, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Company’s securities from listing and registration on Nasdaq. The Company does not intend to appeal the determination and, therefore, it is expected that its Common Stock will be delisted, which would not affect any actions it may take in bankruptcy. Trading of the Common Stock will be suspended by Nasdaq at the opening of business on October 25, 2023.
お知らせ • Oct 19Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI IndexBiocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index
お知らせ • Sep 22Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung CancerBiocept, Inc. announced the full enrollment of 40 subjects with breast or non-small cell lung cancer (NSCLC) who have suspicious or confirmed leptomeningeal metastases (LM) in the feasibility phase of its prospective FORESEE clinical trial (NCT0414123). This trial is evaluating the performance of Biocept's proprietary CNSide assay in monitoring the response to therapy of LM, a cancer in the membranes that surround the brain and spinal cord, and assessing its impact on treatment decisions made by physicians. The FORESEE trial is specifically designed to measure the impact of CNSide on physicians' clinical decisions to generate the data needed to help reach this goal. FORESEE is a two-part prospective clinical trial designed to follow subjects and collect data from each enrollee at four key time points in their treatment, as well as to compare CNSide cell detection in the cerebrospinal fluid to that of conventional cytology. CNSide has notable advantages over current standards of care, such as cytology, clinical evaluation and MRI, which have limited sensitivity and specificity. Biocept expects to have results from the feasibility phase of the FORESEE trial in the first half of 2024 and to then begin enrolling between 40 and 100 subjects in the trial's validation phase. Enrollment is currently open at four clinical sites with two additional sites expected to join the FORESEE trial in The near term.
New Risk • Aug 17New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: US$1.4m This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$19m free cash flow). Share price has been highly volatile over the past 3 months (20% average weekly change). Shareholders have been substantially diluted in the past year (327% increase in shares outstanding). Market cap is less than US$10m (US$2.24m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$9.6m net loss in 3 years). Revenue is less than US$5m (US$1.4m revenue).
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)Second quarter 2023 results: US$3.50 loss per share (improved from US$16.83 loss in 2Q 2022). Net loss: US$3.63m (loss narrowed 62% from 2Q 2022). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US.
お知らせ • Jun 21+ 1 more updateBiocept, Inc. Announces Executive ChangesBiocept, Inc. has named Antonino Morales as President effective immediately. Mr. Morales has served as Biocept's interim Chief Financial Officer since February 2022 and as a Director of the Company since July 2021. Robert Walsh, the Company's Controller, has been promoted to Vice President and Controller and will serve as the Company's principal accounting officer. These changes follow the resignation of Samuel D. Riccitelli as interim President and Chief Executive Officer, and Director. Mr. Morales has served as a member of Biocept's Board since July 2021 and was a member of the Audit Committee from August 2021 until his appointment as interim Chief Financial Officer. He has more than 30 years of broad executive leadership experience and has served in executive management or consulting roles with various Fortune 100 companies, including Citibank, Bank of America, Arthur Andersen, Mazda North America and McDonald's. Mr. Morales has also led multiple private equity-backed startup companies. He received a Bachelor of Science in Finance from the University of Southern California and is a licensed CPA.
お知らせ • May 16Biocept Expects to Receive Non-Compliance Notice Form NasdaqAs reported in Biocept, Inc.'s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on May 10, 2023, the Company's stockholders' equity as of March 31, 2023 was $2.4 million. As a result, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirements set in Nasdaq Stock Market Rule 5550(b) (the Rule"). The Company expects to receive a formal notice (the Notice") from The Nasdaq Stock Market LLC (Nasdaq") on or about May 15, 2023 to formally notify the Company of non-compliance with the Rule. The Company discussed the noncompliance with the Rule with Nasdaq on May 12, 2023. Pursuant to the Notice and Nasdaq rules, the Company will have 45 calendar days after receipt of the Notice to submit a plan to regain compliance with the Rule. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to provide evidence of compliance. There can be no assurance that the Company will be able to regain compliance with the Rule.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.
Breakeven Date Change • Apr 18No longer forecast to breakevenThe 2 analysts covering Biocept no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$5.04m in 2025. New consensus forecast suggests the company will make a loss of US$9.00m in 2025.
分析記事 • Apr 17Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For GrowthThose holding Biocept, Inc. ( NASDAQ:BIOC ) shares would be relieved that the share price has rebounded 48% in the last...
Breakeven Date Change • Feb 14Forecast to breakeven in 2025The 2 analysts covering Biocept expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$5.04m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule.
Valuation Update With 7 Day Price Move • Feb 24Investor sentiment deteriorated over the past weekAfter last week's 15% share price decline to US$2.16, the stock trades at a trailing P/E ratio of 17.8x. Average forward P/E is 12x in the Biotechs industry in the US. Total loss to shareholders of 79% over the past three years.
Reported Earnings • Feb 17Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2021 results: US$0.041 loss per share (up from US$0.37 loss in 3Q 2020). Revenue: US$17.5m (up 165% from 3Q 2020). Net loss: US$624.7k (loss narrowed 87% from 3Q 2020). Revenue exceeded analyst estimates by 8.8%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is expected to shrink by 37% compared to a 187% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has increased by 127% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improved over the past weekAfter last week's 15% share price gain to US$3.95, the stock trades at a trailing P/E ratio of 21.5x. Average forward P/E is 14x in the Biotechs industry in the US. Total loss to shareholders of 65% over the past three years.
分析記事 • Nov 23Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True PositionEven though Biocept, Inc. ( NASDAQ:BIOC ) posted strong earnings recently, the stock hasn't reacted in a large way. We...
Reported Earnings • Nov 17Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$34.9m (up 431% from 3Q 2020). Net income: US$854.1k (up US$5.73m from 3Q 2020). Profit margin: 2.4% (up from net loss in 3Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 128% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
分析記事 • Aug 19Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) EarningsCelebrations may be in order for Biocept, Inc. ( NASDAQ:BIOC ) shareholders, with the covering analyst delivering a...
Reported Earnings • Aug 18Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$12.0m (up US$11.1m from 2Q 2020). Net loss: US$1.83m (loss narrowed 72% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
分析記事 • Jul 03Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time BeingIn the past three years, the share price of Biocept, Inc. ( NASDAQ:BIOC ) has struggled to grow and now shareholders...
Major Estimate Revision • May 19Consensus revenue estimates increase to US$37.5mThe consensus outlook for revenues in 2021 has improved. 2021 revenue forecast increased from US$28.4m to US$37.5m. Forecast losses expected to reduce from -US$1.17 to -US$0.82 per share. Biotechs industry in the US expected to see average net income decline 8.7% next year. Consensus price target of US$12.00 unchanged from last update. Share price was steady at US$4.59 over the past week.
Reported Earnings • May 13First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$17.8m (up US$16.3m from 1Q 2020). Net income: US$2.60m (up US$10.9m from 1Q 2020). Profit margin: 15% (up from net loss in 1Q 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings.
Price Target Changed • May 09Price target decreased to US$12.00Down from US$20.30, the current price target is provided by 1 analyst. New target price is 161% above last closing price of US$4.61. Stock is up 12% over the past year.
Reported Earnings • Mar 31Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: US$27.5m (up 397% from FY 2019). Net loss: US$17.8m (loss narrowed 30% from FY 2019). Over the last 3 years on average, earnings per share has increased by 108% per year but the company’s share price has fallen by 58% per year, which means it is significantly lagging earnings.
分析記事 • Mar 13Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price GainBiocept, Inc. ( NASDAQ:BIOC ) shareholders might be concerned after seeing the share price drop 19% in the last month...
Is New 90 Day High Low • Feb 05New 90-day high: US$6.70The company is up 51% from its price of US$4.45 on 06 November 2020. The American market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
分析記事 • Jan 26We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, Biocept ( NASDAQ:BIOC ) stock...
Is New 90 Day High Low • Jan 20New 90-day high: US$6.23The company is up 38% from its price of US$4.52 on 21 October 2020. The American market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 22% over the same period.
分析記事 • Dec 22Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?With the business potentially at an important milestone, we thought we'd take a closer look at Biocept, Inc.'s...
Reported Earnings • Nov 20Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$6.59m (up 331% from 3Q 2019). Net loss: US$4.88m (loss narrowed 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 71% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Nov 20Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 163%. Earnings per share (EPS) missed analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 154%, compared to a 365% growth forecast for the Biotechs industry in the US.
Reported Earnings • Nov 17Third quarter 2020 earnings released: US$0.43 loss per shareThe company reported a solid third quarter result with reduced losses and improved revenues and control over expenses. Third quarter 2020 results: Revenue: US$6.59m (up 331% from 3Q 2019). Net loss: US$4.88m (loss narrowed 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 101% per year but the company’s share price has fallen by 71% per year, which means it is significantly lagging earnings.
Analyst Estimate Surprise Post Earnings • Nov 17Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 163%. Earnings per share (EPS) missed analyst estimates by 8.5%. Over the next year, revenue is forecast to grow 154%, compared to a 365% growth forecast for the Biotechs industry in the US.
Major Estimate Revision • Nov 14Analysts update estimatesThe 2020 consensus revenue estimate increased from US$8.33m to US$11.7m. Earning per share (EPS) estimate was further reduced from -US$1.35 to -US$2.11 for the same period. The Biotechs industry in the US is expected to see an average net income growth of 6.5% next year. The consensus price target was lowered from US$20.30 to US$20.00. Share price is up 7.4% to US$4.78 over the past week.